Pharmacogenetics at Scale: An Analysis of the UK Biobank.


Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
06 2021
Historique:
received: 10 07 2020
accepted: 22 10 2020
pubmed: 26 11 2020
medline: 11 9 2021
entrez: 25 11 2020
Statut: ppublish

Résumé

Pharmacogenetics (PGx) studies the influence of genetic variation on drug response. Clinically actionable associations inform guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), but the broad impact of genetic variation on entire populations is not well understood. We analyzed PGx allele and phenotype frequencies for 487,409 participants in the UK Biobank, the largest PGx study to date. For 14 CPIC pharmacogenes known to influence human drug response, we find that 99.5% of individuals may have an atypical response to at least 1 drug; on average they may have an atypical response to 10.3 drugs. Nearly 24% of participants have been prescribed a drug for which they are predicted to have an atypical response. Non-European populations carry a greater frequency of variants that are predicted to be functionally deleterious; many of these are not captured by current PGx allele definitions. Strategies for detecting and interpreting rare variation will be critical for enabling broad application of pharmacogenetics.

Identifiants

pubmed: 33237584
doi: 10.1002/cpt.2122
pmc: PMC8144239
mid: NIHMS1650377
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1528-1537

Subventions

Organisme : NHGRI NIH HHS
ID : U24 HG010615
Pays : United States
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : R01 GM102365
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : NLM NIH HHS
ID : T32 LM012409
Pays : United States
Organisme : Stanford University
Organisme : NIGMS NIH HHS
ID : U01 GM061374
Pays : United States

Informations de copyright

© 2020 The Author Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Références

Clin Pharmacol Ther. 2003 Jun;73(6):554-65
pubmed: 12811365
Clin Pharmacol Ther. 2019 May;105(5):1256-1262
pubmed: 30506572
Clin Pharmacol Ther. 2007 Sep;82(3):244-8
pubmed: 17700589
Pharmacogenet Genomics. 2016 Apr;26(4):161-168
pubmed: 26736087
Pharmacogenetics. 2004 Jul;14(7):429-40
pubmed: 15226675
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Clin Pharmacol Ther. 2016 Aug;100(2):160-9
pubmed: 26857349
Hum Mol Genet. 2018 May 1;27(R1):R72-R78
pubmed: 29635477
Nat Genet. 2016 Jul;48(7):811-6
pubmed: 27270109
Nucleic Acids Res. 2019 Jan 8;47(D1):D853-D858
pubmed: 30407534
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
J Mol Diagn. 2016 Jan;18(1):109-23
pubmed: 26621101
Nature. 2020 Oct;586(7831):749-756
pubmed: 33087929
Clin Pharmacol Ther. 2014 Apr;95(4):423-31
pubmed: 24253661
Clin Pharmacol Ther. 2018 Mar;103(3):399-401
pubmed: 29134625
Clin Pharmacol Ther. 2019 Jan;105(1):29-32
pubmed: 30536702
Clin Pharmacol Ther. 2011 May;89(5):662-73
pubmed: 21412232
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
NPJ Genom Med. 2020 Mar 5;5:9
pubmed: 32194983
Hum Genomics. 2018 May 25;12(1):26
pubmed: 29793534
Genet Med. 2019 Jun;21(6):1345-1354
pubmed: 30327539
Genet Med. 2017 Jan;19(1):20-29
pubmed: 27101133
Clin Pharmacol Ther. 2011 Mar;89(3):464-7
pubmed: 21270786
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Bioinformatics. 2011 Aug 1;27(15):2156-8
pubmed: 21653522
Genome Res. 2012 Jan;22(1):1-8
pubmed: 22147369
PLoS Comput Biol. 2020 Nov 2;16(11):e1008399
pubmed: 33137098
Clin Pharmacol Ther. 2020 Jan;107(1):203-210
pubmed: 31306493
Int J Mol Sci. 2020 Mar 26;21(7):
pubmed: 32225115
J Pharmacol Exp Ther. 2002 Aug;302(2):804-13
pubmed: 12130747
J Biol Chem. 2001 Sep 21;276(38):35669-75
pubmed: 11477075
Clin Pharmacol Ther. 2020 Mar;107(3):617-627
pubmed: 31594036
Pharmacogenomics J. 2019 Apr;19(2):115-126
pubmed: 30206299

Auteurs

Gregory McInnes (G)

Biomedical Informfatics Training Program, Stanford University, Stanford, California, USA.

Adam Lavertu (A)

Biomedical Informfatics Training Program, Stanford University, Stanford, California, USA.

Katrin Sangkuhl (K)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

Teri E Klein (TE)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
Department of Medicine, Stanford University, Stanford, California, USA.

Michelle Whirl-Carrillo (M)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

Russ B Altman (RB)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
Departments of Bioengineering, Genetics, and Medicine, Stanford University, Stanford, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH